{
    "clinical_study": {
        "@rank": "93946", 
        "acronym": "RELIEF", 
        "arm_group": [
            {
                "arm_group_label": "Precision Plus", 
                "description": "Subjects permanently implanted with a Boston Scientific Precision Plus neurostimulation system"
            }, 
            {
                "arm_group_label": "Alternative Boston Scientific systems", 
                "description": "Subjects permanently implanted with other Boston Scientific neurostimulation systems"
            }
        ], 
        "brief_summary": {
            "textblock": "To compile characteristics of real-world clinical outcomes for Boston Scientific\n      commercially approved neurostimulation systems for pain in routine clinical practice, when\n      used according to the applicable Directions for Use\n\n      - and -\n\n      To evaluate the economic value and technical performance of Boston Scientific  commercially\n      approved neurostimulation systems for pain in routine clinical practice"
        }, 
        "brief_title": "RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "The study is a prospective, multi-center, global registry of Boston Scientific\n      neurostimulation systems for pain.\n\n      The study treatment will consist of neurostimulation trial therapy with any commercially\n      approved Boston Scientific Corporation neurostimulator for pain.  Positive trials, subjects\n      with a successful trial outcome, may progress to permanent implant of a neurostimulation\n      system.  Individualization of neurostimulation therapy for pain will be determined according\n      to investigator discretion and site routine care, and in accordance with inclusion and\n      exclusion criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Study candidate is scheduled to be trialed, on-label, with a commercially approved\n             Boston Scientific neurostimulation system for pain, per local directions for use\n\n          -  Signed a valid, IRB/EC-approved informed consent form\n\n          -  18 years of age or older\n\n        Key Exclusion Criteria:\n\n          -  Contraindicated for Boston Scientific neurostimulation system\n\n          -  Currently diagnosed with cognitive impairment, or exhibits any characteristic, that\n             would limit study candidate's ability to assess pain relief or to complete study\n             assessments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who exhibit an on-label indication for neurostimulation to relieve chronic\n        intractable pain, according to the Directions for Use, as applicable in each country or\n        region"
            }
        }, 
        "enrollment": {
            "#text": "4800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719055", 
            "org_study_id": "A7007", 
            "secondary_id": "CDM00052418"
        }, 
        "intervention": {
            "arm_group_label": [
                "Precision Plus", 
                "Alternative Boston Scientific systems"
            ], 
            "description": "Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome", 
            "intervention_name": "neurostimulation system", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stimulation", 
            "implantable", 
            "pulse generator", 
            "back pain", 
            "chronic pain", 
            "leg pain"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "email": "BSNClinicalTrials@bsci.com", 
                "phone": "855-213-9890"
            }, 
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91355"
                }, 
                "name": "Boston Scientific Clinical Research Information Toll Free Number"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain", 
        "other_outcome": [
            {
                "description": "Change in employment as reported by the Subject", 
                "measure": "Work Productivity", 
                "safety_issue": "No", 
                "time_frame": "from Baseline to 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Change in medical resource utilization", 
                "measure": "Resource Utilization", 
                "safety_issue": "No", 
                "time_frame": "from Baseline to 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Rate of device-related and procedure-related Adverse Events (AEs) from trial lead insertion through completion of study", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Rate of Serious Adverse Events (SAEs) from informed consent through completion of study", 
                "measure": "Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }
        ], 
        "overall_contact": {
            "email": "Ann.Masuda@bsci.com", 
            "last_name": "Ann Masuda, M.S.", 
            "phone": "(661) 949-4726"
        }, 
        "overall_contact_backup": {
            "email": "Diane.Bowers@bsci.com", 
            "last_name": "Diane Bowers", 
            "phone": "(661) 949-4175"
        }, 
        "overall_official": {
            "affiliation": "Boston Scientific Corporation", 
            "last_name": "Roshini Jain, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subject-reported percent pain relief of targeted pain at 6 months post neurostimulation trial", 
            "measure": "Percent pain relief", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719055"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent pain relief of targeted pain as reported by the Subject", 
                "measure": "Percent pain relief", 
                "safety_issue": "No", 
                "time_frame": "End of Neurostimulation Trial, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Change in intensity of targeted pain as reported by the Subject", 
                "measure": "Change in pain intensity", 
                "safety_issue": "No", 
                "time_frame": "from Baseline to End of Neurostimulation Trial, 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Change in physical functioning as reported by the Subject", 
                "measure": "Change in physical functioning", 
                "safety_issue": "No", 
                "time_frame": "from Baseline to 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Change in quality of life as reported by the Subject", 
                "measure": "Change in QoL", 
                "safety_issue": "No", 
                "time_frame": "from Baseline to 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Clinical global impression as reported by the physician", 
                "measure": "Global impression", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Subject global impression as reported by the Subject", 
                "measure": "Subject global impression", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Change in depression as reported by the Subject", 
                "measure": "Depression", 
                "safety_issue": "No", 
                "time_frame": "from Baseline to 12 and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Paresthesia coverage of targeted pain (a tingling sensation associated with neurostimulation therapy) as reported by the Subject", 
                "measure": "Paresthesia Coverage", 
                "safety_issue": "No", 
                "time_frame": "End of neurostimulation trial, IPG implantation, 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Change in the total amount of physician-prescribed, pain-related medications used", 
                "measure": "Medications", 
                "safety_issue": "No", 
                "time_frame": "from Baseline  to  6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Satisfaction with treatment as reported by the Subject", 
                "measure": "Subject Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "at  End of neurostimulation trial, IPG implantation, 6, 12, 24, and 36 months post neurostimulation trial"
            }, 
            {
                "description": "Progression to permanent implantation with a Boston Scientific neurostimulation system by 12 months post neurostimulation trial", 
                "measure": "Trial to Permanent Implantation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patient ease of use of the implanted system, as reported by the Subject", 
                "measure": "Ease of Use", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}